Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) regularly issues news on its RNA interference (RNAi) pipeline, regulatory milestones, clinical data, and capital markets activity. This ARWR news page on Stock Titan aggregates those updates so readers can follow how the company’s gene-silencing therapeutics are progressing across cardiometabolic, obesity, and neurodegenerative indications.
Recent company announcements highlight approvals and regulatory actions for REDEMPLO (plozasiran), a small interfering RNA medicine targeting apoC-III for adults with familial chylomicronemia syndrome (FCS). Arrowhead has reported approvals for REDEMPLO in the United States, Canada, and China, as well as Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia and ongoing Phase 3 trials in broader triglyceride disorders.
News items also cover interim clinical data for investigational obesity candidates ARO-INHBE and ARO-ALK7, which the company is studying for effects on visceral fat, total fat, liver fat, and body weight, including in obese patients with type 2 diabetes mellitus. Additional coverage includes the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies such as Alzheimer’s disease, using a TRiM-based delivery system intended to reach the central nervous system after subcutaneous administration.
Investors and observers will also find Arrowhead’s press releases on public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032, as well as collaboration and licensing updates such as the agreement with Novartis for ARO-SNCA and arrangements involving Visirna Therapeutics and Sanofi in Greater China. Bookmark this page to review Arrowhead’s earnings-related 8-K references, conference participation, and ongoing disclosures about its RNAi programs and commercial activities.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Janssen Pharmaceuticals presented clinical data from the REEF-1 Phase 2b study at The Liver Meeting. The study assessed combination therapies, including JNJ-3989 and JNJ-6379, for chronic hepatitis B infection. Key findings highlighted a dose-dependent response, with 19.1% of patients meeting NA stopping criteria at week 48. The JNJ-3989 200 mg cohort showed a 2.6 log10 reduction in HBsAg at week 48. Overall, treatments were well-tolerated, and additional combination studies are underway.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented additional Phase 1/2 clinical data for ARO-APOC3 at the American Heart Association's Scientific Sessions 2021. The investigational RNA interference therapy targets apolipoprotein C-III and aims to treat hypertriglyceridemia. Key findings include a 98% reduction in APOC3 among familial chylomicronemia patients and well-tolerated administration across various doses. The therapy demonstrated significant decreases in triglycerides and increases in HDL-C, suggesting it as a promising option for patients with severe hypertriglyceridemia.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented interim clinical data from its AROHSD1001 study at The Liver Meeting, showcasing ARO-HSD's potential for treating liver diseases like NASH. Key findings included a dose-dependent reduction in HSD17B13 mRNA, with over 90% reduction at 200 mg in all patients. Additionally, liver fat reductions were noted in 9 out of 18 patients. ARO-HSD was well-tolerated, with no serious adverse events linked to the drug. This investigational therapy aims to leverage RNA interference to combat liver diseases effectively.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced interim clinical data from the ongoing AROAAT2002 study of ARO-AAT, a treatment for alpha-1 antitrypsin deficiency. Key outcomes include a 72-100% reduction in liver Z-AAT protein and notable improvements in liver fibrosis in 6 out of 14 patients. Additionally, the treatment successfully reduced histological globule burden and normalized liver health biomarkers. No significant adverse events were reported, indicating a favorable safety profile. Arrowhead is collaborating with Takeda, receiving $300 million upfront, with potential milestone earnings of $740 million.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a conference call and webcast on November 22, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal year ending September 30, 2021. Investors can access the live audio via the company's website at ir.arrowheadpharma.com. A replay will be available for 90 days post-call. Arrowhead focuses on developing RNAi-based therapeutics to treat intractable diseases through gene silencing technology.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is scheduled to participate in several key events from November 12-30, 2021. Highlights include presentations during the Liver Meeting (AASLD) featuring findings on ARO-AAT and ARO-HSD therapies, as well as results from the Phase 2B REEF-1 Study for chronic hepatitis B. Additionally, CEO Chris Anzalone will engage in fireside chats at both the Jefferies London Healthcare Conference and the Piper Sandler Healthcare Conference. These events underline Arrowhead’s commitment to advancing RNA interference therapeutics.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application for clearance to initiate a Phase 1/2a clinical trial of ARO-C3, an investigational RNA interference therapeutic for complement-mediated diseases. The trial aims to evaluate safety and pharmacokinetics in healthy volunteers and patients with specific renal conditions. Arrowhead will host a KOL webinar on October 26, 2021, to elaborate on ARO-C3's development and its potential to treat unmet medical needs in renal and hematology diseases, including IgA nephropathy and paroxysmal nocturnal hemoglobinuria.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a KOL webinar on October 26, 2021, at 3:00 p.m. ET to discuss ARO-C3, an investigational RNAi therapeutic for complement mediated diseases. Presenters include experts Richard J. Glassock and Peter Browett, who will cover treatment landscapes and unmet needs in renal and hematological complement mediated diseases. The management team will explain preclinical data and clinical plans, aiming to file a CTA in Q4 2021 for clinical studies. Access the webinar on Arrowhead's website under Events and Presentations.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing for the first patient in the AROAPOC3-2002 Phase 2b study of ARO-APOC3, targeting adults with mixed dyslipidemia. This investigational RNAi therapeutic aims to address severe hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia syndrome. As part of its clinical program, Arrowhead plans to start a Phase 3 study for patients with familial chylomicronemia syndrome in Q4 2021. Approximately 320 participants will be enrolled in the ongoing study.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events in October 2021. On October 4, Vince Anzalone will join a fireside chat at Chardan's 5th Annual Genetics Medicines Conference. Following that, on October 12, James Hamilton will present at the H.C. Wainwright 5th Annual NASH Investor Conference. For detailed presentation materials and live webcast links, visit the Events and Presentations section on Arrowhead's website.